Multimorbidity is common and associated with adverse outcomes in heart failure (HF). However, its prognostic value across frailty states is uncertain, particularly whether comorbidities continue to stratify risk once frailty develops.
To evaluate whether frailty modifies the association of multimorbidity i...
V. Copeland, B. Fishman, S. Elimelech et al.· European Heart Journal· 0 citations
Frailty is a multidimensional syndrome of reduced physiologic reserve associated with adverse outcomes in heart failure (HF). Whether its underlying drivers and prognostic significance differ by age remains poorly understood.
To assess age-specific correlations of frailty, predictors of incident frailty, a...
V. Copeland, B. Fishman, S. Elimelech et al.· European Heart Journal· 0 citations
AI-derived CV biological age from FoCUS identifies subclinical cardiometabolic vulnerability independent of chronological age in asymptomatic adults, and may enhance personalized risk profiling and guide early preventive interventions in asymptomatic adults.
R. Amster, D. Simanovsky, R. Loutati et al.· European Heart Journal· 0 citations
Artificial intelligence (AI)-based left ventricular ejection fraction (LVEF) estimation compares reasonably well with conventional readings. We assessed its prognostic value in the standard transthoracic echocardiography (TTE) and point-of-care-ultrasound (POCUS) settings.
AI-based LVEF estimation was retr...
K. Faierstein, R. Loutati, M. Fiman et al.· European Heart Journal· 0 citations
Assessment of left ventricular diastolic dysfunction (LVDD) and filling pressure is standard in echocardiography but remains time- and expertise-dependent. We evaluated the performance and prognostic significance of an artificial intelligence (AI)-enabled echocardiography for LVDD grading.
An AI model was...
R. Loutati, M. Fiman, A. Amshalom et al.· European Heart Journal· 0 citations
Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder defined by the overlapping burden of heart failure (HF), chronic kidney disease (CKD), diabetes, and obesity. Although sex differences in cardiovascular disease are increasingly recognized, sex-specific patterns of mortality and renal progressi...
D. Hochstein, R. Loutati, V. Copeland et al.· European Heart Journal· 0 citations
OBJECTIVE
This study aimed to evaluate the risk of clinically meaningful muscle- and liver-related outcomes associated with concomitant colchicine-statin therapy in a real-world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone.
METHODS
A retros...
R. Meidan, R. Loutati, D. Caspi et al.· Arthritis care & research· 0 citations
Patients with advanced chronic kidney disease (CKD) and heart failure (HF) are systematically underrepresented in clinical trials despite comprising a substantial proportion of real-world HF populations [1]. Whether contemporary care has translated into improved outcomes in this high-risk group particularly among...
D. Hochstein, D. Sternik, V. Copeland et al.· European Heart Journal· 0 citations
Deep learning applied to sinus-rhythm TTE demonstrates discrimination for AF and identifies an imaging-derived signal associated with subsequent AF documentation and adverse outcomes.
I. Cohen, M. Fiman, R. Loutati et al.· European Heart Journal - Dig...· 0 citations
Left ventricular hypertrophy is a hallmark of adverse remodeling in heart failure (HF), yet commonly used echocardiographic measures provide limited insight into sex-specific risk. Interventricular septal (IVS) thickness is routinely measured, but its independent prognostic value and potential sex-related differe...
A. Kaplan, V. Copeland, R. Loutati et al.· European Heart Journal· 0 citations
In patients with late-stage metabolic syndrome, CKD identifies a high-risk subgroup with a graded increase in mortality and dialysis risk compared with eGFR ≥60, and the heightened dialysis risk remained pronounced after accounting for competing death.
D. Hochstein, R. Loutati, V. Copeland et al.· European Heart Journal· 0 citations
In patients with heart failure and advanced chronic kidney disease, CCBs use was associated with improved survival, supporting their potential role as a safe adjunctive therapy for blood pressure control in this high-risk population.
V. Copeland, A. Milwidsky, S. Elimeleh et al.· American Journal of Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.